Multiple Myeloma Hub

Multiple Myeloma Hub

Por: Scientific Education Support
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.
75 episodios disponibles

Latest episodes of the podcast Multiple Myeloma Hub

Clinical experience with belantamab mafodotin: Management strategies for ocular toxicity 23/10/2025
MIDAS: MRD-driven strategy after Isa-KRd induction in ND ASCT-eligible MM 22/10/2025
How might the clinical development of CELMoDs impact the treatment paradigm for MM? 20/10/2025
CARTITUDE-2: Cilta-cel ± Len maintenance for MM with suboptimal response to ASCT 03/10/2025
Evolving diagnostic criteria for high-risk smoldering MM 30/09/2025
What combination regimens including BiTEs are being evaluated for the treatment of RRMM? 17/09/2025
Risk stratification and prognosis in smoldering MM 10/09/2025
What combination regimens containing BCMA-directed bispecific antibodies are being evaluated for MM? 09/09/2025
How can neurotoxicity associated with CAR T-cell therapy in MM be managed? 26/08/2025
What might be the future applications for BCMA-directed bispecific antibodies in MM and other PCD? 18/08/2025
What is the rationale for early intervention in high-risk smoldering MM? 30/06/2025
How are BCMA-directed bispecific antibodies currently utilized in real-world practice for MM? 17/06/2025
MRD in MM: Implications for clinical practice and trial design 16/06/2025
Targeting XPO1 for the treatment of MM: Real-world evidence 09/06/2025
How to incorporate novel therapies into the treatment paradigm for early RRMM? 30/05/2025
What are the future perspectives for anti-CD38 mAbs in the treatment of MM? 19/05/2025
What are the current treatment recommendations and unmet needs in early RRMM?  13/05/2025
What is the rationale for treating early RRRM with targeted therapies? 02/05/2025
What is the impact of belantamab mafodotin on QoL in patients with MM? 30/04/2025
What is the impact of elranatamab on quality of life in relapsed/refractory multiple myeloma? 29/04/2025
1 2 3 4 Siguiente › Última »
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA